在非复杂疟疾中,阿特罗兰和皮佩拉奎因与阿特梅瑟和卢梅芬特林相比:尼日利亚的一项随机研究
Olufunsho Awodele1, Ibrahim Sebutu Bello2, Babatunde Abdulmajeed Akodu3
1Department of Pharmacology, Therapeutics and Toxicology Faculty of Basic Medical Sciences, University of Lagos-Nigeria.
概括
阿特罗兰酸-皮佩拉奎因酸 (AMP) 在治疗尼日利亚患者无并发性Plasmodium falciparum疟疾时,其疗效和安全性与Artemether-lumefantrine (AL) 相当. 这两种治疗都实现了高治愈率,在关键结果或不良事件中没有显著差异.
科学领域:
- 热带医学 热带医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 在尼日利亚,不复杂的Plasmodium falciparum疟疾仍然是一个重大的公共卫生问题.
- 阿尔特梅瑟-卢姆芬特林 (AL) 是一种标准的治疗方法,但需要其他有效和安全的选择.
- 阿特罗兰马莱酸盐-皮佩拉奎因酸盐 (AMP) 呈现出一种潜在的替代治疗方案.
研究的目的:
- 在尼日利亚患者中比较Arterolane maleate-Piperaquine phosphate (AMP) 与Artemether-lumefantrine (AL) 的疗效和安全性.
- 评估治疗结果,包括临床和寄生虫学反应率.
- 评估与两种抗疟疾治疗相关的安全性和不良事件.
主要方法:
- 第四期,随机化,多中心,开放标签,主动控制的研究.
- 350名年龄在12-65岁之间的没有并发症的P. falciparum疟疾患者被随机分配 (1:1).
- 患者每天接受一次AMP或每天两次AL3天,结果评估到第42天.
主要成果:
- 到28日,AMP和AL都实现了100%的PCR校正的充分临床和寄生虫学反应 (ACPR),持续到42日.
- 不经PCR校正的ACPR率很高,在各组之间可比 (AMP:98.2%,AL:28.日99.4%).
- 在发烧清除时间,寄生虫清除时间或与药物相关的不良事件中没有发现显著差异.
结论:
- 每天服用一次阿特罗兰酸-皮佩拉奎因酸 (AMP) 与每天两次服用阿尔特梅瑟-卢梅方特林 (AL) 一样有效和安全,用于治疗无并发症的P. falciparum疟疾.
- AMP提供了一个可行的替代治疗选择,具有类似的安全性.
- 这项研究支持AMP在疟疾治疗方案中的使用.
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...